Sectors: Healthcare, Pharma & Life Sciences

Deal & transactions

VISCHER advises Versantis on its sale to Gentif

Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit. With this acquisition, Genfit intends to expand its product portfolio with a Phase 2 ready programme based on first-in-class scanning liposome technology, a paediatric programme focused on urea cycle disorder […]

Banking & Finance

Advestra advises Gnothis on Financing Rounds

Advestra has advised Gnothis on all legal aspects related the two financing rounds of nearly CHF 10 million. Gnothis Holding is a com­pany act­ive in the health sec­tor and has closed this fin­an­cing rounds this year. Investors include the invest­ment com­pany Nord­stjernan and the indus­tri­al group Hüb­n­er Group. Gnothis, which is based in Cham, is a pion­eer in the devel­op­ment […]

Banking & Finance

VISCHER advises Mosanna Therapeutics on its Seed Financing Round

Mosanna Therapeutics, a Basel-based biotechnology company, has closed a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of the molecule MOS118 and for regulatory activities in preparation of the first Phase 1b clinical trial. Mosanna is developing the advanced small molecule MOS118, formerly know as AVE0118, […]

Deal & transactions

Lenz & Staehelin on the acquisition of Nizell Medical

As we announced on February, Promedical, which was acquired earlier this year by a group of investors led by SME Equity Partners and Co-Investor Partners and acting through its parent company, has acquired Lauerz-based Nizell Medical. With this transaction the group further consolidates its position in the Swiss medical consumables market and becomes a leading […]

Banking & Finance

Engimmune Therapeutics raises CHF 15.5m in seed financing round 

Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch.  Engimmune Therapeutics is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment.  Proceeds from the financing will be used to develop novel T-cell […]

Capital Markets

KSA Group on sustainable financing by a CHF 120 million

KSA Group has taken another important step on the way to the new green building “Dreiklang”, KSA’s new ecological construction project. The KSA Group was able to raise CHF 120 million on the capital market by issuing its first green bond. The offering, which was developed under the leadership of UBS and with the Basellandschaftliche […]

Deal & transactions

Astorg signs binding agreement with ICIG to acquire CordenPharma

Private equity firm Astrog has entered into a binding agreement with privately owned industrial group International Chemical Investors Group (“ICIG”) whereby Astorg will acquire CordenPharma, a global pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with highly differentiated capabilities in Active Pharmaceutical Ingredients, Excipients, and Drug Products, from ICIG. As part of the transaction, the founders […]

Banking & Finance

CDR-Life raises USD 76 million in its Series A Financing

CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital Management, with participation from Omega Funds. Homburger advised CDR-Life in the transaction. The Homburger team was led by partner […]

Capital Markets News

Advestra: GBL acquires a majority stake in Sanoptis

Groupe Bruxelles Lam­bert (GBL) acquires a major­ity stake in San­optis, a net­work of oph­thal­mo­logy clin­ics across Ger­many and Switzer­land, from the private equity Telemos Cap­it­al. GBL is com­mit­ting up to EUR 750 mil­lion in equity for this trans­ac­tion with the aim to accelerate the company’s growth in partnership with its management and doctors. In this sense, as part of the transaction, the […]